Highlights d Inducible split protein mouse models to quantify a-synuclein oligomerization in vivo d Aging promotes accumulation of size-defined a-synuclein oligomers d a-synuclein oligomerization takes place at the presynapse d Cell-to-cell transmission of a-synuclein is demonstrated in an intact mouse brain
INTRODUCTION
Parkinson's disease (PD) is a progressive neurodegenerative disease with age being the strongest risk factor. Loss of dopaminergic neurons in the substantia nigra and other parts of the nervous system together with the presence of intra-neuronal in-clusions called Lewy bodies or Lewy neurites are main characteristics of PD. Aggregates of a-synuclein (a-syn) are the main component of Lewy bodies and Lewy neurites. a-Syn is closely linked to PD pathogenesis since several mutations in a-syn (A30P, E46K, A53T, A53E, G51D, and H50Q) or solely increased gene dosage of a-syn are sufficient to cause familial forms of PD (Rosborough et al., 2017) .
Although the exact mechanism of a-syn toxicity remains unknown, accumulating evidence suggests that the precursors of deposited a-syn, oligomers and fibrils, are the toxic species in PD (Dehay et al., 2015; Fusco et al., 2017; Winner et al., 2011; Auluck et al., 2010) . Moreover, post-translational modifications including C-terminal cleavage (Sung et al., 2005) , oxidation, nitration (Hodara et al., 2004) , and phosphorylation (Fujiwara et al., 2002; Paleologou et al., 2010) might contribute to oligomerization, fibrillization, and toxicity (Barrett and Timothy Greenamyre, 2015) .
a-Syn assemblies released from neurons can propagate in a prion-like manner by seeding aggregation of endogenous a-syn in neighboring cells. Several in vitro (exposure of cells to a-syn oligomers or fibrils) and in vivo experiments (injection of synthetic preformed fibrils or brain homogenates derived from diseased mice or from PD patients, cell transplantations, and viral overexpression of a-syn) support seeded aggregation and interneuronal transmission of a-syn (Danzer et al., 2007 (Danzer et al., , 2009 (Danzer et al., , 2011 Desplats et al., 2009; Hansen et al., 2011; Volpicelli-Daley et al., 2011; Luk et al., 2012a Luk et al., , 2012b Rey et al., 2013; Holmqvist et al., 2014; Ulusoy et al., 2013) . These findings underline the observations by Braak et al. (2003) , describing that a-syn inclusion body pathology in PD occurs in a hierarchical distribution, starting in the stomach and propagating to axonally connected areas.
While strategies to study spreading of a-syn in vivo were to date mainly based on exogenous injection of a-syn in mouse Figure 1 . Characterization of Conditional S1/S2 and V1S/SV2 Mice (A and B) Schematic diagram of the two conditional protein-fragment complementation assay (PCA) mouse models S1/S2 (A) and V1S/SV2 (B). Expression is driven by neuron specific CaMKIIa promoter in a Tet-off system. For S1/S2, human wild-type a-syn is tagged with either N-or C-terminal part of hGaussia luciferase. For V1S/SV2, Venus YFP halves are fused to a-syn. (C and D) Western blot of 24-month-old S1/S2 (C) and V1S/SV2 (D) brains using a-syn clone 42 (BD) and pSyn#64 (WAKO) antibodies. Loading control: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Brains were dissected according to Figure S1A . OB, olfactory bulb; CTX, cortex; MB, midbrain/basal ganglia; CB, cerebellum; BS, brainstem; and SC, spinal cord. (E) Pole test analysis of S1/S2 animals showed age-associated motor impairment (n = 15 male mice; repeated-measures two-way ANOVA, ***p % 0.001). TTurn = time to turn and orientate downward on the pole. First significant impairments for TTurn were detected at 14.5 months (Mann-Whitney U test; p < 0.05). Data: mean ± SEM. (F) Progressive aggravation in motor balance and coordination in S1/S2 animals (n = 15 male mice, repeated-measures two-way ANOVA, ***p % 0.001). First significant impairments were observed at 11.7 months (t test; p < 0.05). Data: mean ± SEM. (G) Beam walk analysis revealed significant balance dysfunction in S1/S2 expressing mice during aging (n = 15 male mice, repeated-measures two-way ANOVA, ***p % 0.001). Earliest significant impairment was observed at 16.8 months (t test; p < 0.05). Data: mean ± SEM. (H and I) Striatal dopamine concentration of S1/S2 (H) and V1S/SV2 (I) animals was measured by HPLC coupled with electrochemical detection (ECD). Significant reduction of dopamine was detected at 24 months for a-syn overexpressing mice (n = 6-10 mice per group and time point; two-way ANOVA with Sidak's post hoc test; *p % 0.05; ns = not significant). Bars: mean ± SEM. (J) Representative tyrosine hydroxylase (TH) staining in the substantia nigra of V1S/SV2 mice. (K and L) The number of TH-positive neurons was counted in the substantia nigra pars compacta of S1/S2 (K) and V1S/SV2 (L) mice using two different methods (please see STAR Methods for details). For method A, TH + cell loss was estimated at 5 (n = 5 mice per group) and 24 months of age (n = 6 mice per group), two-way ANOVA with Sidak's post hoc test, *p % 0.05, ns = not significant. For method B, TH + cell loss was stereologically counted in 24-month-old mice using the optical fractionator method (S1/S2: n = 5-6 mice per group, V1S/SV2: n = 6-8 mice per group). Two-tailed unpaired t test. All data: mean ± SEM. brain, evidence for cell-to-cell spreading of a-syn in transgenic models is rare. We and others have previously demonstrated that protein-fragment complementation assays (PCAs) such as bimolecular fluorescence complementation or split luciferase reporter systems are powerful tools for studying protein-protein interactions and monitoring the formation of a-syn oligomers and aggregation directly in vitro and in vivo (Danzer et al., 2011; Putcha et al., 2010; Outeiro et al., 2008; Dimant et al., 2013; Cai et al., 2018; Delenclos et al., 2016; Aelvoet et al., 2014) . We have now generated two human a-syn transgenic neuronspecific mouse models designed in a Tet-off system combined with a PCA, using a split luciferase and a split Venus YFP system.
With this experimental approach, we evaluated the effect of aging on a-syn oligomer formation, defined the cellular compartment of aggregation, and studied cell-to-cell spreading of a-syn in vivo. Furthermore, we determined neuropathological, neurochemical, and behavioral changes upon a-syn oligomer generation. Our transgenic mouse models are valuable tools for understanding the mechanistic interplay between aging, a-syn oligomerization, and spreading, which will promote new therapeutic approaches in PD.
RESULTS

Generation of a-Syn Oligomer Mice
In order to monitor a-syn oligomerization in vivo we made use of a bioluminescent protein complementation assay. To that end, the N-terminal and C-terminal halves of Gaussia luciferase were fused to wild-type (WT) human a-syn (named S1 and S2, respectively). Oligomerization of a-syn leads to reconstitution of Gaussia luciferase, resulting in the production of bioluminescence upon administration of the substrate coelenterazine. Moreover, for the development of a fluorescent PCA Venus YFP was fragmented into N-and C-terminal parts then fused each with WT a-syn to form non-fluorescent fusion proteins V1S and SV2, respectively. In analogy to bioluminescent PCA, non-fluorescent V1S and SV2 reconstitute to fluorescent Venus YFP when a-syn oligomerizes (Dimant et al., 2013; Danzer et al., 2011) .
For in vivo application a transgenic mouse model with a tetracycline regulated S1 and S2 expression (Tet-off) was generated (Gossen and Bujard, 1992) . S1 and S2 were placed under the control of a tetracycline response element (TRE) with a bidirectional CMV min promoter, which regulates the expression of both S1 and S2. These single transgenic S1/S2 mice were then crossbred with the CaMKIIa-tTA driver line in order to induce S1 and S2 expression in neurons of different forebrain areas (Mayford et al., 1996a ) ( Figure 1A ). To avoid any transgene expression during embryonic development, animals were bred and housed in the presence of doxycycline (dox) until birth.
Analogous to the WT a-syn split luciferase system, conditional transgenic V1S/SV2 mice ( Figure 1B ) were generated to allow cellular resolution of a-syn oligomer formation. In order to analyze expression of S1/S2 and V1S/SV2, mouse brains of 24-month-old mice were dissected in six different brain regions ( Figure S1A ). For both mouse lines, forebrain areas with olfactory bulb, cortex, and midbrain featured strong expression of human a-syn, whereas hindbrain areas showed moderate to very weak expression levels ( Figures 1C and 1D ). In V1S/SV2 brains, we detected a-syn dimers/multimers that have been described previously for the split Venus YFP system and were absent in S1/S2 mouse lines (refer to Figure S1B ) (Kim et al., 2016; Eckermann et al., 2015; Cai et al., 2018) . Conditional transgene expression of S1/S2 as well as V1S/SV2 was confirmed by dox treatment of mice. In both mouse lines, human a-syn protein levels were roughly fourfold higher than endogenous a-syn on western blot ( Figure S1C ). To further assess a-syn pathology in S1/S2 and V1S/SV2 mice, a phospho-specific antibody was used. Phosphorylated a-syn modification at serine 129 is predominantly found in Lewy bodies and is associated with disease-promoting mechanisms in PD (Oueslati, 2016; Anderson et al., 2006) . Extensive p-Ser-129 a-syn signals could be observed in olfactory bulb, cortex, and midbrain in both S1/S2 as well as V1S/SV2 mice (Figures 1C and 1D) .
Behavioral analysis of S1/S2 expressing mice showed significant differences compared to dox treated mice in the pole test (two-way repeated-measures ANOVA; p < 0.001) (Figures 1E and S1D). Also motor coordination, assessed in the accelerating rotarod ( Figure 1F ) and beam walking test (Figures 1G and S1E) , differed significantly between the two groups (two-way repeated-measures ANOVA; p < 0.001). Moreover, hindlimb clasping testing ( Figure S1F ) demonstrated that S1/S2 expressing mice partially retracted hindlimbs toward the abdomen, starting from 13 months on (two-way repeated-measures ANOVA; p < 0.001).
In the open field, a-syn overexpressing mice showed reduced locomotor activity and exploratory behavior (Figures S1G-S1K). In addition, a reduced anxiety-like behavior was observed in the elevated plus maze, as they had the propensity to stay longer in open arms than control animals (Figures S1L and S1M). We addressed V1S/SV2 animal motor behavior by running wheel activity ( Figure S1N ) and already observed between 8 and 12 months of age a decreased activity for a-syn expressing mice compared to control (two-way repeated-measures ANOVA; p < 0.001).
Olfactory dysfunction as an early non-motor symptom in PD (Doty, 2012) was tested in both mouse lines using a buried food test. As illustrated in Figures S1O and S1P, the time to uncover the buried sunflower seeds for S1/S2 mice was significantly longer at 20-24 months of age and V1S/SV2 mice already showed first alterations at 12-16 months of age (two-way repeated-measures ANOVA; p < 0.001).
(M) Representative striatal TH staining in V1S/SV2 mice. (N and O) Striatal TH-immunoreactivity quantification of S1/S2 (N) and V1S/SV2 (O) mice at 5 (n = 5 mice per group) and 24 months of age (n = 6 mice per group). Intensities of tissue sections stained simultaneously were compared. Data: mean ± SEM; paired t test; *p % 0.05; ns = not significant). (P) Unsupervised hierarchical clustering of 24-month-old V1S/SV2 transgene expressing (on) and doxycycline treated mice (off), using 10,000 differentially expressed genes. Colors represent overexpression (yellow) or downregulation (blue). See also Figures S1 and S2 and Tables S1, S2, and S3.
In accordance with these behavioral phenotypes we detected age-dependent alterations of the dopaminergic system in mice expressing S1/S2 or V1S/SV2. In contrast to the pre-symptomatic phase (7 months), a significant reduction of striatal dopamine and elevated levels of striatal dopamine metabolites using high-performance liquid chromatography (HPLC) analysis as well as a reduction of striatal dopaminergic fibers were detected in the striatum at 24 months for both S1/S2 and V1S/SV2 mice ( Figures 1H, 1I , 1M, 1N, 1O, and S1Q) whereas serotonin (5-HT) concentrations and the turnover rate were not changed ( Figure S1R ). Dopamine and 5-HT concentrations in the substantia nigra were not significantly altered for both S1/S2 and V1S/ SV2 mice (Figures S1S-S1U). Furthermore, a mild loss of dopaminergic neurons in the substantia nigra using two methods for tyrosine hydroxylase (TH) cell number determination of S1/S2 expressing mice at 24 months of age was observed (Figures 1J and 1K) thus underlining deficits in the dopaminergic system. For 24-month-old V1S/SV2 mice, cell counting of TH-immunopositive neurons reached a significant reduction with method A whereas optical fractionator (method B) did not reach statistical significance (p = 0.166) ( Figure 1L ).
To also characterize our V1S/SV2 mouse model on a transcriptomic level, sequencing of whole-brain RNA lysates was performed ( Figures 1P and S2 ; Tables S1, S2, and S3). Interestingly, out of 25 relevant significantly altered pathways identified in PD patients versus age-matched healthy controls (Elstner et al., 2011) , 22 were also significantly altered in our V1S/SV2 mouse model. Within the highly significant altered mitochondrial dysfunction pathway, we even detected an overlap of individual genes of more than 51% with PD patients, emphasizing the value of these mice as a model for PD.
Detection of an 8-16-mer Oligomeric Subfraction In Vivo
To analyze a-syn oligomers in vivo, protein complementation in S1/S2 brain extracts was determined using a luciferase assay. Elevated levels of Gaussia luciferase activity indicative for a-syn oligomers were found in olfactory bulb, cortex, and midbrain areas and moderate to low levels in cerebellum, brainstem, and spinal cord ( Figure 2A ). No luciferase activity could be detected in body fluids (cerebrospinal fluid, whole blood, serum, plasma, or urine) or other organs (gut, stomach, liver, spleen, kidney, heart, or testis) .
In contrast to conventional methods, like SDS-PAGE, our approach allowed us to determine the exact sizes of different a-syn species in the brains of S1/S2 mice: Using size-exclusion chromatography (SEC) combined with luciferase activity measurement and dot blot detection of total a-syn in each fraction, we identified a heterogeneous profile of a-syn oligomers. The strongest luciferase signal corresponded to 8-16 mer (in fractions of 10-13 ml) ( Figure 2B ). Luciferase signals and dot blot (human a-syn specific 15G7 antibody) signals peaked in different fractions (11 and 15 ml, respectively). This suggested that the 8-16-mer a-syn oligomers were highly enriched compared to the total amount of a-syn in vivo.
Age-Dependent Accumulation of a-Syn Oligomers
Age is the most prominent risk factor for PD. Therefore, we determined whether age has an impact on a-syn oligomer formation and applied homogenates of different brain areas from 1-, 12-, and 24-month-old S1/S2 mice to SEC with subsequent luciferase activity measurements and dot blot analysis (human a-syn specific 15G7 antibody) of the respective fractions (Figure 3A) . We found a dramatic increase in 8-16-meric oligomers in 24-month-old mice compared to 12-and 1-month-old animals. In midbrain (comprising hippocampus [HC], caudoputamen [CP], globus pallidus interna/externa [GPi/e], thalamus, and substantia nigra pars reticulata [SNpr]; see Figure S1A ), a considerable number of oligomers larger than 30 mer was formed during aging. In low expressing hindbrain areas (cerebellum, brainstem, and spinal cord), we found a similar pattern with a high percentage of oligomers corresponding to 16 to 4 mers (fractions from 9.5 to 12.5 ml) that were formed with age. Also, quantification of total luciferase activity per brain area (Figure 3B) points to an age-dependent increase of a-syn oligomers. The finding of accumulation of a-syn oligomer species with age led us to categorize the S1/S2 oligomers into subclasses (large, medium, and small oligomers, tetramers, dimers, and a-syn fragments). When we calculated the percentages of the total oligomer count ( Figure 3C ), we found a stepwise decrease of smaller In Vivo Using the S1/S2 PCA Mouse Model (A) Normalized Gaussia luciferase activity measurements of S1/S2 brain area lysate. 12-16 months of age (n = 7 mice per group). Brain dissection according to Figure S1A . Data: mean ± SEM, Mann-Whitney U test, ***p % 0.001. (B) Representative luciferase activity of size-exclusion chromatography (SEC) fractions of full-brain lysate of S1/S2 animal (19.5 months of age) and dot blot analysis (anti-human a-syn 15G7 antibody) of SEC fractions (5.9-16.9 ml). Luciferase assay reveals enrichment of 8-16-mer species. Figure 3 . Age-Dependent Increase of 8-16-mer a-Syn Oligomer Species (A) Luciferase activity measurement of SEC fractions of different brain areas of 1 month (blue), 12 months (green), 24 months (red), and doxycycline treated (purple) S1/S2 mice shows age-dependent accumulation of 8-16-mer oligomer species. Dot blot analysis of respective SEC fractions (5.46-14.96 ml) was performed using anti-human a-syn 15G7 antibody. Graph depicts mean of n = 3 mice per group. (B) Quantification of total luciferase activity of all SEC fractions per brain area demonstrates an age-dependent increase of a-syn oligomers (area under the curve equivalent; one-way ANOVA with Tukey's post hoc test, *p % 0.05, **p % 0.01; data: mean ± SEM).
(legend continued on next page) oligomers and simultaneously a stepwise increase of larger oligomers during aging for the olfactory bulb and midbrain. To distinguish whether the age-dependent increase in luciferase activity results from an increase in a-syn protein or from increased gen-eration of a-syn oligomers, densitometry of dot blots using human a-syn antibody was performed. No significant difference in total a-syn between 24-, 12-, and 1-month-old S1/S2 mice could be observed ( Figure S3A) , indicating an increased a-syn oligomer load with aging.
Subcellular Distribution of a-Syn Oligomers In Vivo Next, we used the V1S/SV2 mouse model for subcellular resolution of a-syn oligomer formation. Reconstituted fluorescent Venus YFP could be detected in defined fore-and midbrain areas, particularly in the olfactory bulb, cortex, hippocampal formation, caudoputamen, globus pallidus, thalamus, and the substantia nigra pars reticulata ( Figure 4A ), which was abolished by treatment with dox. To also confirm the presence of aggregated a-syn in the V1S/SV2 mouse brain, sections were stained with Syn-O2 antibody, which is specific for aggregated a-syn and stains Lewy bodies and neurites in human tissue (Vaikath et al., 2015) . As demonstrated in Figure 4B , immunohistochemistry confirmed the presence of aggregated a-syn species in V1S/ SV2 animals. To determine the Proteinase K sensitivity of a-syn aggregates in the brains of 24-month-old V1S/SV2 mice, immunohistochemical analysis was performed in sections after treatment with different Proteinase K conditions. Here, oligomeric a-syn immunoreactivity was considerably reduced, suggesting the presence of Proteinase K soluble a-syn species in V1S/SV2 mice ( Figure 4B ). Incubation of brain lysate with Proteinase K and subsequent western blot analysis confirmed the soluble nature of V1S/SV2 oligomers in fore-and hindbrain regions ( Figure 4C ).
To underline the pathophysiological relevance of a-syn oligomers in our mouse model, additional stainings using p-Ser-129 antibody and oligomer-specific Syn-O2 and 5G4 antibodies were performed. Since both oligomeric antibodies Syn-O2 and 5G4 were validated to detect aggregated a-syn in human PD tissue (Kovacs et al., 2012; Vaikath et al., 2015) , the high degree of colocalization with V1S/SV2 (84% and 81%, respectively), as well as the strong overlap to p-Ser-129 (77%), underlines the pathological characteristics of formed V1S/SV2 oligomers.
We noticed that Venus YFP reconstitution could be detected solely in fore-and midbrain areas with high synaptic densities and not in the soma or nuclei of neurons. Staining of sagittal brain sections with the presynaptic marker Bassoon revealed the synaptic localization of V1S/SV2 fluorescence ( Figure S3B ). At large hippocampal mossy fiber synapses, which are 2-5 mm in diameter (Zhao et al., 2012) , many a-syn Venus YFP oligomer puncta colocalized with Bassoon signal. In contrast, staining with the postsynaptic marker Homer1 showed a significantly decreased colocalization compared to presynaptic marker Bassoon (Figures 5A and 5B) . In addition, the synaptically localized oligomers were mainly composed of human a-syn (15G7 antibody). A partial overlap with endogenous mouse a-syn, as shown by D37A6 antibody staining, also suggests a possible formation of (C) Percentage of SEC luciferase activity of (A) grouped into a-syn oligomer subclasses shows for OB and MB a stepwise increase of large oligomers and a decrease of smaller oligomers with age. Classification: large oligomers (%96 mer, >48 mer), medium oligomers (%38 mer, >15 mer), small oligomers (%15 mer, >6 mer), tetramers (%6 mer, R3 mer), dimers (<3 mer, >1 mer), and monomers/fragments (%1 mer). One-way ANOVA with Tukey's post hoc test, *p % 0.05, **p % 0.01; data: mean ± SEM. See also Figure S3 . (A) Sagittal V1S/SV2 mouse brain sections showing repression of transgene expression by doxycycline (off) and successful complementation of V1S and SV2 in transgene expressing mice (on; green fluorescence) in the olfactory bulb, hippocampus, cortex, caudoputamen, globus pallidus interna/externa, thalamus, and substantia nigra pars reticulata (12-month-old mice; DAPI in blue). (B) Immunostaining of sagittal V1S/SV2 brain sections (age: 24 months) with anti-aggregated a-syn Syn-O2 antibody and treatment with different Proteinase K conditions demonstrates the solubility of a-syn oligomers. (C) Western blot (a-syn clone 42 [BD] antibody) and corresponding Ponceau S staining of forebrain (FB) and hindbrain (HB) treated with or without Proteinase K of V1S/SV2 expressing versus wild-type mouse (age: 20 months) showed solubility of V1S/SV2 oligomers. Blots reflect representative result of three independent experiments. heteromers containing both human and mouse a-syn (Figures 5A and 5B) . To further characterize the localization of human a-syn, we carried out a post-embedding immunogold labeling of ultrathin sections of the striatum ( Figure 5C ). Electron micrographs (EMs) confirmed a presynaptic localization of transgenic human a-syn, mainly at the vesicle reserve pool but also close to the active zone of the presynapse. Surprisingly, EM pictures also indicated a potential postsynaptic or extrasynaptic localization of human a-syn ( Figure 5C, arrows) , which is in agreement with a possible transsynaptic propagation of a-syn.
a-Syn pathology has been described at the synapse (Soukup et al., 2018) ; however, the site of oligomer formation is still a matter of debate. In V1S/SV2 expressing mice we found phosphorylated Syn-O2 positive V1S/SV2 aggregates solely located at synaptic terminals but not in the cytoplasm of neurons expressing the transgene. We thus hypothesized that a-syn could be present in the cytoplasm, but in an unaggregated state and therefore lacking V1S/SV2 fluorescence. Indeed, immunofluorescent staining clearly demonstrated the presence of cytoplasmic human a-syn in granule cells of the dentate gyrus, which were lacking the V1S/SV2 signal ( Figure 5D , 1, upper row). Reconstituted V1S/SV2 fluorescence signal was only observed in mossy fiber terminals in the hilus and at projection terminals to pyramidal neurons in CA3 ( Figure 5D , 2, lower row). This indicates that cytoplasmic a-syn is not in an oligomeric state, while the presynapse represents a site for oligomerization that gives rise to pathologically relevant a-syn species in vivo.
Cell-to-Cell Transmission of a-Syn
Cell-to-cell transmission of a-syn has been suggested before, but respective experiments were limited to in vitro studies, based on injection of exogenously formed a-syn fibrils or transplanted a-syn producing cells (Luk et al., 2012a (Luk et al., , 2012b Rey et al., 2013; Holmqvist et al., 2014; Ulusoy et al., 2013; Desplats et al., 2009; Hansen et al., 2011; Volpicelli-Daley et al., 2011; Danzer et al., 2009 Danzer et al., , 2007 . In contrast, our models offer the chance to assess the propagation of a-syn expressed and formed in host cells in vivo.
Assuming a transsynaptic cell-to-cell propagation of a-syn, we postulated the possible existence of cells that were immunopositive for human a-syn protein without the expression the transgenic mRNA (see below; Figure 6E ), but with synaptic input from brain areas expressing the transgene. Since the CaMKIIa promoter is primarily limited to glutamatergic forebrain neurons, we searched predominantly in the hindbrain areas for neurons fulfilling these criteria. To avoid autofluorescence artifacts 3,3 0 -diaminobenzidine (DAB) staining was used for these experiments. Indeed, in the deep cerebellar nuclei (interposed nucleus, fastigial nucleus receiving input from Purkinje layer; Figure 5 . a-Syn Aggregation and Oligomer Formation in the Presynaptic Compartment (A) Confocal co-staining of V1S/SV2 aggregates in the hilar mossy fiber terminals of the dentate gyrus with presynaptic marker Bassoon, postsynaptic marker Homer1, a-syn aggregate specific Syn-O2 and 5G4 antibodies, human a-syn 15G7 antibody, p-S129-a-syn antibody, and mouse a-syn specific antibody D37A6. Scale bar: 5 mm. (B) Quantification of (A) using the ImageJ Colocalization Colormap plugin. The index of correlation represents the fraction of positively correlated pixels (n = 13-25 stainings using 3-5 mice; one-way ANOVA with Tukey's post hoc test, ***p % 0.001; data: mean ± SEM). (C) Immunogold staining of striatal synapse with anti-human a-syn 15G7 antibody. Representative electron micrographs show the presynaptic localization of a-syn in transgene expressing mice. Potential postsynaptic or extrasynaptic localization of a-syn is indicated with arrows.
(D-1) Staining for human a-syn (15G7) in the dentate gyrus detects cytoplasmic localization of human a-syn in granule cells that were negative for reconstituted V1S/SV2 signal, indicating that cytoplasmic human a-syn is not aggregated. Scale bar: 10 mm. (D-2) Colocalization of V1S/SV2 (green) and human a-syn antibody staining (15G7, red) in the projection terminals of granule cells to the pyramidal cells of hippocampal CA3 region supports synaptic aggregation and localization. Scale bar: 10 mm. See also Figure S3 . Figure 6 . Prion-Like Spreading of a-Syn Aggregates In Vivo (A) Immunostaining for human a-syn (4B12) in sagittal brain sections of adult V1S/SV2 mice ± doxycycline (24 months of age). Although most hindbrain neurons are not expressing CaMKIIa (Mayford et al., 1996b (Mayford et al., , 1996a , neurons of the deep cerebellar nuclei and facial brainstem nucleus were positively stained for cytoplasmic human a-syn. (B) Quantification of cytoplasmic human a-syn staining intensity using ImageJ, n(on)=9 stainings/4 mice, n(off)=10 stainings/3 mice. Data: mean of intensities normalized to transgene off ±SEM, 2way ANOVA with Sidak's post hoc test. ***p%0.001. (C) Immunostaining for aggregated a-syn (Syn-O2) in sagittal brain sections of adult V1S/SV2 mice ±doxycycline (24 months of age) highlights oligomeric conformation in CB and BS neurons. (D) Confocal microscopy showed that punctuate cytoplasmic human asyn aggregates were located within CB and BS neurons (stained with human asyn (15G7) and NeuN). (E) RNAscope in situ hybridization of V1S/SV2 sagittal brain section using a custom designed Venus ISH probe, positive control ISH probe and negative control ISH probe. Images are representative results from the same animal stained simultaneously, demonstrating the absence of transgene mRNA in deep cerebellar nuclei and brainstem facial motor nucleus. Bottom panel shows dual staining of Venus mRNA (red, ISH) and human a-syn protein (brown, 4B12 antibody, IHC) on V1S/SV2 tissue section. (F) Quantification of (E) RNAscope in situ hybridization, n=4 mice per group. Data normalized to negative control, 2way ANOVA with Tukey's post hoc test. **p%0.01, ***p%0.001, ns=not significant; data: mean ±SEM. Figure S4A ) and in the brainstem-associated facial motor nucleus (receiving cortical input; Figure S4A ) we found neurons containing cytoplasmic human a-syn protein ( Figures 6A and  6B ), suggesting a neuron-to-neuron spreading of a-syn protein.
These neurons were also reactive to oligomeric a-syn antibody Syn-O2 ( Figure 6C ). Additional application of confocal fluorescence microscopy showed that cytoplasmic a-syn aggregates were localized in the perinuclear region ( Figure 6D ). To exclude the possibility of a potential Venus-tag-dependent effect, we also studied the transmission of a-syn in S1/S2 mice. Quantification of human a-syn in deep cerebellar nuclei and facial motor nucleus also confirmed spreading of a-syn in S1/S2 mice (Figure S4B ). In addition, we asked whether endogenous mouse a-syn is transmitted along human a-syn. In hindbrain neurons where we observed transmitted human a-syn (deep cerebellar nuclei and brain stem motor nucleus), endogenous mouse a-syn is expressed. Since this makes it difficult to distinguish between transmitted and expressed mouse a-syn, quantification did not reach statistical significance ( Figure S4C ). Importantly, we aimed to exclude any leaky promoter activity in the deep cerebellar and in the brainstem-associated facial motor neurons.
To that end, we used RNAscope in situ hybridization (ISH) for the sensitive detection of Venus YFP mRNA sequences. Brain sections of non-transgenic, WT animals showed reactivity only to the positive control probe but did not react to our Venus YFP target ISH probe, demonstrating its sensitivity ( Figures 6F,  S5E, S5F, and S5G) . In contrast to the anticipated CaMKIIa promoter-driven abundant Venus YFP mRNA expression in hippocampal neurons, deep cerebellar and brainstem facial motor nucleus neurons were clearly negative for Venus mRNA ( Figures  6E, 6F , and S5C). To further corroborate that cytoplasmic human a-syn in these neurons is not due to leaky transgene expression but rather a consequence of a-syn protein spread from neuron to neuron, we combined classic immunohistochemistry (IHC) staining against human a-syn with ISH on the same tissue section ( Figures 6E, bottom panel, and S5D ). Again, we could identify deep cerebellar nuclei and brainstem facial motor nucleus neurons positive for human a-syn but negative for transgene mRNA on the same tissue section. However, transmission of transgenic a-syn is not only restricted to hindbrain areas, since we also observed in thalamic areas intracellular accumulations of human a-syn in neurons that did not express the transgene mRNA ( Figure S6) .
To further exclude a leaky transgene expression in the previously mentioned hindbrain neurons by an alternative method, we applied laser capture microdissection (LCM) followed by DNase treatment and RT-PCR. Quantification of CaMKIIa with exon-exon spanning primers was additionally used as an indirect readout for transgene expression, since Venus YFP transgene lacks introns. We found that only in full-brain RNA lysate and hippocampal RNA were robust amounts of CaMKIIa and Venus YFP mRNA detected, whereas deep cerebellar nuclei neurons (cere-bellum [CB]) and facial motor nucleus neurons (brainstem [BS]) were devoid of Venus YFP and CaMKIIa mRNA ( Figures 6G-6I ). We thereby provided additional evidence to exclude that leaky expression of a-syn in hindbrain neurons is the reason for the a-syn content in these neurons and corroborated the hypothesis of neuron-to-neuron spreading from Venus-YFP-a-syn expressing forebrain neurons to hindbrain neurons.
Since we observed a dopamine deficiency in aged mice, we asked if human a-syn oligomers were present in the cytoplasm of SNpc neurons. Confocal fluorescence microscopy clearly demonstrated intracellular a-syn aggregates (Figures 7A, arrow heads, and 7B) in TH-positive neurons in transgene expressing animals that were absent when transgene expression was turned off. Intriguingly, we did not detect Venus transgene mRNA (red, ISH staining; asterisks) in TH-positive neurons of the SNpc (brown, IHC TH staining; arrows) ( Figure 7B ). Instead, only smaller, TH-negative neurons in the SNpc had detectable Venus transgene mRNA (Lacey et al., 1989; Nedergaard and Greenfield, 1992) . Because the red ISH staining can be difficult to distinguish from brown IHC (TH immunostaining), we took advantage of the fluorescent properties of the red Venus probe dye to separate the signals but still did not detect any dopaminergic neurons expressing the Venus transgene mRNA. A plausible explanation for this finding is that de novo generated human a-syn oligomers can spread from transgene expressing glutamatergic afferents of the SNpc to dopaminergic SNpc neurons.
DISCUSSION
We present two transgenic mouse models that allow for directly assessing the quantity and subcellular distribution of a-syn oligomers in vivo. Using these mice, we demonstrate an agedependent accumulation of a-syn oligomers of a defined size and can directly track their localization to the synaptic site in vivo. Furthermore, we provide in vivo evidence for cell-to-cell transfer of a-syn oligomers from forebrain to hindbrain neurons, without injection of proteins into the tissue or using allogeneic transplanted cells.
Although great effort has been expended to characterize a-syn oligomers in in vitro and also in vivo models using biochemical methods like SDS-PAGE, the full picture of a-syn oligomer characteristics in vivo is still not clear. While SDS-PAGE or antibody-based techniques reflect only a subset of a-syn oligomers, our approach using size-exclusion chromatography combined with luciferase measurements unveils the existence of the whole range of different a-syn oligomers in various brain regions in vivo. Our animal models not only prove generation of different a-syn oligomers de novo in vivo, but also identify an enrichment of a 12-mer oligomeric a-syn. This accumulation of 12 mer was specifically enhanced with age, while the total amount of a-syn protein was not increased in old animals. This age-dependent alteration in the a-syn oligomer profile was (H) RT-PCR analysis of laser capture microdissected cells using primers for V1S transgene, CaMKIIa as an indirect readout for promoter activity and GAPDH. Full brain RNA lysate of V1S/SV2 mice served as positive control. NTC=no template control. One lane was removed (dotted line). (I) Quantification of PCR result of laser capture microdissected cells in (G/I) using ImageJ, n=3, 2way ANOVA with Tukey's post hoc test. **p%0.01, ***p%0.001, ns=not significant; data: mean ±SEM. See also Figures S4, S5 , S6, and S7. paralleled by a late onset, progressive motor decline, and a loss of dopaminergic neurons in S1/S2 mice.
Our study cannot provide a final proof for a causative link between a-syn oligomers, TH cell numbers, and/or behavioral alterations. Nevertheless, our data are in line with the study of Nuber et al. (2008) , who also used a CaMKIIa-driven conditional a-syn mouse model and reported that even a small nominal change in dopaminergic neurons might account for a clinical phenotype. For 24-month-old S1/S2 mice, we observed a reduced anxietylike behavior that is similar to a previously described transgenic a-syn mouse model (George et al., 2008) . Reduced striatal dopamine levels have recently been reported to cause less anxiety (Wenzel et al., 2018) , which directly links the observed phenotype in S1/S2 mice to a lack of dopamine. However, the question remains whether monomeric or oligomeric a-syn provokes dopamine depletion in our model. Since the overall amount of human a-syn remained constant over time but the oligomeric profile changed in S1/S2 mice, we hypothesize that the oligomeric species interferes with synaptic signaling and dopamine homeostasis.
Our RNA sequencing (RNA-seq) approach revealed a remarkable similarity with RNA-seq data from laser captured dopaminergic SNpc neurons of PD patients (Elstner et al., 2011) . Cellular processes in the aged human brain, along with increased levels of a-syn during aging in nigral neurons (Chu and Kordower, 2007) , might also lead to a massive increase in a-syn oligomers in humans. Aging is the most prominent risk factor for the development of PD (Baldereschi et al., 2000; de Lau and Breteler, 2006; Collier et al., 2011) . Therefore, a higher oligomeric load of a-syn during aging might be an explanation for a higher vulnerability for PD upon aging.
Strong evidence indicates that synaptic pathology is central in PD (Calo et al., 2016) . In patients with dementia with Lewy bodies many a-syn aggregates are located at the synapse, leading to synaptic impairment and neurodegeneration (Kramer and Schulz-Schaeffer, 2007) . Moreover, a-syn accumulation at presynaptic terminals affects neurotransmitter release and redistribution of presynaptic proteins in an age-dependent manner (Burré , 2015;  Kramer and Schulz-Schaeffer, 2007; Garcia- Reit-bö ck et al., 2010; Busch et al., 2014) , even prior to the death of dopaminergic neurons (Bridi and Hirth, 2018) . While it has been speculated that a-syn accumulation in presynaptic terminals causes synaptopathy with subsequent ''dying back'' of neurons, we were able to demonstrate that a-syn oligomerization takes place at the presynapse and not in the a-syn protein containing cytoplasm in vivo. This finding also suggests an aggregation-promoting environment in the presynaptic compartment. The result that most V1S/SV2 aggregates were recognized by oligomerspecific antibodies such as Syn-O2 and 5G4, which bind also to human a-syn oligomers, further suggest that V1S/SV2 oligomers share important properties with pathological forms of a-syn in humans. We demonstrated the presence of Ser129phosphorylated a-syn oligomers at the presynapse in vivo, consistent with previous data detecting p-Ser129-a-syn-positive aggregates at the presynapse in dementia with Lewy bodies patients (Colom-Cadena et al., 2017) . Together, this identifies the synapse as a pathophysiologically relevant cellular compartment in PD. However, it remains an interesting question whether a-syn aggregates are formed at synapses to fulfill a physiological function, as suggested by Wang et al. (2014) , whether they have detrimental effects, or both. A reorganization of a-syn into multimers at synapses has also been observed before using V1S/SV2 transfected hippocampal neurons .
However, the detection of V1S/SV2 oligomers mainly at presynaptic terminals in both our V1S/SV2 mouse model and the study by Wang et al. is in contrast to two other studies (Dimant et al., 2013; Cai et al., 2018) . In this case, a-syn oligomers were detected in cell bodies of neurons, as detected by a Venus YFP fluorescence complementation system. This discrepancy can be plausibly explained by the use of adeno-associated viral vectors to target overexpression of V1S/SV2 to the soma of nigral neurons under the control of a highly active chicken b-actin promoter in both studies (Dimant et al., 2013; Cai et al., 2018) . In contrast, moderate V1S/SV2 expression was achieved in our mouse model by the CaMKIIa promoter, or by a molecular replacement strategy achieving endogenous levels of a-syn in the study by Wang et al. (2014) . Aggregated and oligomeric a-syn are also implicated in prionlike transmission of PD pathology between distant axonally connected brain regions (Jucker and Walker, 2013) . According to the hypothesis by Braak et al. (2003) , spread of a-syn pathology follows connected brain areas. Consistent with this hypothesis, we detected cytoplasmic human a-syn accumulation in neurons of the deep cerebellar nuclei and in neurons of the brainstem facial motor nucleus despite the absence of transgenic mRNA, as shown by in situ hybridization and RT-PCR of laser capture microdissected cells.
These neurons receive afferent projections from distant neurons expressing the transgene, which is in agreement with a possible transsynaptic spread of a-syn ( Figure S7 ). In addition, electron microscopy of human a-syn immunogold labeled striatal sections depicted extra-neuronal a-syn, which would be consistent with a neuron-to-neuron transmission. Furthermore, although the CaMKIIa promoter is active in glutamatergic but not dopaminergic neurons (Liu and Murray, 2012) , we found dopaminergic neurons that harbored human a-syn aggregates. This provides a further argument for spreading of a-syn from transgene expressing glutamatergic neurons to dopaminergic neurons in the substantia nigra.
In summary, we have generated two non-invasive inducible transgenic mouse models that allow the direct quantification and subcellular visualization of a-syn oligomers in vivo. Employing these in vivo tools, we demonstrate an age-dependent increase of distinct a-syn oligomer species, their presence at the synapse, and ultimately the spread of a-syn oligomers to distant, axonally connected neuronal populations in vivo.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
ACKNOWLEDGMENTS
We thank T. Christ, R. Bueck, and A. Jesionek for excellent work. We thank F. Roselli for ISH assistance. We also thank the Core Facility for transgenic animals and for Laser Microscopy at Ulm University. Moreover, we are grateful to R. Marienfeld from CCCU for the opportunity to work with the Zeiss 
DECLARATION OF INTERESTS
The authors declare no competing interests.
LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources, reagents, and mice should be directed to and will be fulfilled by the Lead Contact Karin Danzer (karin.danzer@uni-ulm.de) . Transfer of materials may require a material transfer agreement (MTA) to be signed.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Ethical Statement
Mouse experiments were performed in accordance with provisions of the German Animal Welfare Act (Tierschutzgesetz) and in line with the local guidelines of the Animal Research Center, Ulm University.
Generation of Transgenic Animals
Constructs for S1, S2 and V1S, SV2 (described previously in Danzer et al., 2011) were cloned into multiple cloning sites of the pBI5 bidirectional vector downstream of the tetracycline response element (TRE). Vectors were linearized with BsrBI, DNA fragments were purified from agarose gel with UltraClean 15 DNA Purification Kit (MO BIO, Carlsbad, CA, US) and 2 ng/ml were injected into the pronucleus of fertilized oocytes. Transgenic founder lines were crossbred with mice expressing the tetracycline transactivator (tTA) under control of the Calcium/calmodulin-dependent protein kinase II a (CaMKIIa) promoter B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ obtained from Jackson Laboratory. Transgenic offspring were genotyped by PCR of tail DNA using the following oligonucleotides for TRE sequence. S1/S2 animals: S1/S2_For: 5 0 -CAC CGA GAA CAA CGA AGA CTT-3 0 ; S1/S2_Rev: 5 0 -CGT CCT GGG ATG AAC TTC TT-3 0 . V1S/SV2 animals: V1S/SV2_For: 5 0 -ACA TGA AGC AGC ACG ACT TCT-3 0 ; V1S/SV2_Rev: 5 0 -ACG TTG TGG CTG TTG TAG TTG TA-3 0 . For tTA sequence: tTA_For: 5 0 -CGC TGT GGG GCA TTT TAC TTT AG-3 0 ; tTA_Rev: 5 0 -CAT GTC CAG ATC GAA ATC GTC-3 0 .
Housing and Gender of Mice Used in the Analyses Animals were housed at the Animal Research Center, Ulm University under standardized conditions (SPF) with food/water ad libitum and a 14/10 h light/dark cycle. Transgene expression was turned off with 100 mg/l doxycycline in the drinking water, sweetened with 10 g/l glucose. For transgene expression, animals were given water supplemented with 10 g/l glucose after weaning.
Male mice were used for behavioral tests, RNA-seq, TH stereology, TH striatal density measurements, western blot analysis, immunohistochemistry, and in situ hybridization. Female mice were used for electron microscopy. Balanced mixed sex groups were used for HPLC dopamine concentration analysis, size-exclusion chromatography, and luciferase activity assays.
Protein Complementation Assay
For S1/S2 line, Gaussia luciferase is split in two parts and each part is fused to human wild-type a-syn. Both parts, S1 and S2, are expressed simultaneously. For V1S/SV2 line, the fluorescent protein VenusYFP is split and each non-fluorescent part is fused to a-syn (V1S and SV2). Upon a-syn oligomerization, the reporter parts form a functional reconstituted bioluminescent active luciferase (S1/S2) or a fluorescent VenusYFP protein (V1S/SV2). In both lines, transgene expression is designed in a Tet-off system inducible manner, driven by the neuronal specific CaMKIIa promoter (Mayford et al., 1996a) . Application of doxycycline ceases transgene expression ( Figures 1A and 1B) .
METHOD DETAILS
RNA Isolation for RNA Sequencing RNA isolation was performed using the miRNeasy Mini Kit (QIAGEN, Venlo, Netherlands) following manufacturer's instructions with initial 700 ml Qiazol / 50 mg tissue and DNase digestion. RNA sequencing was carried out by Next-Generation-Sequencing Core Unit Erlangen. The quality of reads was assessed using FastQC. Adaptor sequences and stretches with low quality were then removed using cutadapt with the settings -a AGATCGGAAGAGC -q 20,20-minimum-length 50-trim-n-max-n = 0.1, followed by another round of FastQC. Reads mapping to tRNA or rRNA sequences (obtained from RepBase, mapped with bwa) were discarded. Following another filtering step with fqtrim, reads were mapped to the reference genome using STAR. ENSEMBL GRCm38 (UCSC mm10) served as reference genome and version 85 of the ENSEMBL annotation set for mm10 was used. Indexing of the aligned .bam files was done using samtools 1.3.1. Expression matrices were then generated using the featureCounts routine of subread 1.5.3. Differential expression calls were obtained from DESeq2 with standard settings. The resulting expression matrices were annotated using Germany) solution for 5 s. After blueing, sections were dehydrated in ascending ethanol series, incubated in Xylol and mounted with DPX (Sigma-Aldrich, St. Louis, MO, USA). Images were recorded using a MIRAX Desk slide scanner (Zeiss, Oberkochen, Germany).
The following primary antibodies were used for histology:
Electron Microscopy and Immunogold Labeling
Mice were deeply anaesthetized with ketamine (WDT, Garbsen, Germany)/xylazine (Bayer, Leverkusen, Germany) and transcardially perfused with PBS and 4% PFA. Brains were dissected and 150 mm vibratome sections were used to punch out striatal areas. After high-pressure freezing, samples were freeze-substituted with 0.06% uranyl acetate and 5% H 2 O in acetone, washed with À20 C propanol and embedded in LR-gold resin. Ultrathin sections (80 nm) were blocked with ImmunoBlock (Carl Roth, Karlsruhe, Germany) for 10 min and primary antibody anti-human a-Synuclein (15G7, rat, dilution 1:5; Enzo, Farmingdale, NY, USA) was incubated for 30 min. Samples were washed in blocking solution 6x2 min and treated with 10 nm gold labeled secondary antibody goat anti-rat IgG (1:50, cross-adsorbed with mouse; Aurion, Wageningen, Netherlands) for 30 min. After washing in blocking solution for 3x2 min and PBS 3x2 min, samples were fixed in 1% glutaraldehyde, washed 4x2 min in ddH 2 O, contrasted with 1% uranyl acetate and washed in ddH 2 O. Images of ultrathin immunogold labeled sections were recorded using a JEM-1400 transmission electron microscope (Jeol, Akishima, Japan) equipped with a Veleta digital camera (Olympus Soft Imaging Solutions GmbH, M€ unster, Germany) and iTEM software (Olympus Soft Imaging Solutions GmbH, M€ unster, Germany).
Proteinase K Treatment
Sagittal 12 mm mouse brain sections were incubated with 25 or 50 mg/ml Proteinase K (Thermo Fisher Scientific, Waltham, MA, USA) in 10 mM Tris HCl pH 7.8; 100 mM NaCl; 0.2% SDS for 15 and 30 min at 37 C, followed by staining procedure as described previously.
Brain lysates of 24 months old V1S/SV2 mice or wild-type controls were incubated with 25 mg/ml Proteinase K for 5 min, followed by Western blot procedure as described above.
RNAscopeâ In Situ Hybridization (ISH) Mice were anaesthetized with ketamine (WDT, Garbsen, Germany)/xylazine (Bayer, Leverkusen, Germany), transcardially perfused with PBS, brains were dissected, embedded in Tissue-Tekâ O.C.T (Sakura, Leiden, Netherlands), immediately frozen on dry ice and stored at À80 C for a short period of time (up to 4 weeks). Sagittal 12 mm mouse brain sections were cut on a cryostat and slides were temporary stored at À80 C. In situ hybridization was carried out with RNAscope 2.5 HD Detection Reagent -RED (ACD, Newark, CA, USA) and was performed according to manufacturer's instructions for fresh frozen tissue. Positive control probe targeting mRNA of PPIB housekeeping gene, negative control probe binding to mRNA of bacterial dapB gene as well as custom designed specific target probe for VenusYFP N terminus were purchased from ACD. For dual ISH + IHC staining, RNAscope standard protocols were applied. Primary antibody concentrations: mouse anti-a-Synuclein 4B12 (Biolegend, San Diego, CA, USA) 1:50; rabbit anti-Tyrosine Hydroxylase AB152 (Merck, Darmstadt, Germany) 1:200. HRP-conjugated goat secondary antibodies (Thermo Fisher Scientific, Waltham, MA, USA) were used at 1:250.
Laser Capture Microdissection
Briefly, sagittal mouse brain cryostat sections (12 mm) were placed on UV light pre-treated PEN membrane slides, washed in PBS for 5 min, stained with Mayer's hemalum solution (Merck, Darmstadt, Germany) and dehydrated in ascending ethanol series and stored at À80 C overnight. Laser capture microdissection was performed using a PALM MicroBeam system (Zeiss, Oberkochen, Germany). Cells were collected in PCR tubes (AdhesiveCap 200 opaque, Zeiss, Oberkochen, Germany) and stored for a short time at À80 C (up to 1 week). RNA isolation was performed using the PicoPure RNA Isolation Kit (Thermo Fisher Scientific, Waltham, MA, USA) with DNase treatment. cDNA synthesis was carried out with iScript cDNA Synthesis Kit (Bio-Rad) with subsequent PCR using the following primers: Venus_For: 5 0 -GAC GAC GGC AAC TAC AAG AC-3 0 , Venus_Rev: 5 0 -CCA CCA TCG ATC TGC TTG TC-3 0 ; CaMKIIa_For: 5 0 -CAG CAT CCC AGC CCT AGT TC-3 0 , CaMKIIa_Rev: 5 0 -CCC CAC CAG TAA CCA GAT CG-3 0 ; GAPDH_For: 5 0 -AGT ATG ACT CCA CTC ACG GCA A-3 0 , GAPDH_Rev: 5 0 -ATA CTC AGC ACC GGC CTC ACC-3 0 . PCR was verified by agarose gel electrophoresis. Accelerating rotarod (five lane rotarod, Med Associates) was adjusted to increase from 4 to 40 rpm over a period of 300 s and was carried out in three consecutive trials with 5 min break in between. The latency to fall was recorded and mean values were used for analysis.
Electrophoresis
The beam walk analysis setup was constructed as depicted in Carter et al. (2001) . Time to cross the round wooden beam (diameter: 11 mm) as well as number of hindlimb foot slips were recorded.
We assessed hindlimb clasping response and scoring according to Guyenet et al. (2010) . Animals were grasped at the base of the tail, lifted for 10 s and hindlimb position was observed. Score of 0 means hindlimbs were constantly splayed outward. For score of 1, one hindlimb was retracted toward the abdomen for more than 5 s. For both hindlimbs retracted toward the abdomen for more than 5 s, the animal received a score of 2. Total retraction of both hindlimbs and contact to the abdomen for more than 5 s resulted in a score of 3. The test was performed at distinct time points with 3 consecutive trials with 5 min break intervals. Average values were used for analysis.
To address a potential reduced olfaction in our animals, we performed a buried food test according to Yang and Crawley (2009) , using sunflower seeds (Seeberger, Ulm, Germany) as palatable food. Briefly, animals were fasted over night for 12 h but fed two consecutive days before with four sunflower seeds for odor familiarization. On the test day, S1/S2 animals were placed in a clean test cage with new bedding, acclimated for 5 min and were transferred temporarily to a transition cage when four sunflower seeds were buried together 3 cm underneath the bedding in alternating corners of the test cage. The animals were reintroduced to the test cage and latency to uncover the seeds was recorded. The recording time was stopped when animals scored the max. value of 300 s searching. V1S/SV2 animals, housed individually due to running wheel activity, were tested in their home cage.
Running wheel activity was monitored (V1S/SV2 animals) with ''Maus Vital'' software (Laser-und Medizin-Technologie Berlin, Berlin, Germany). Mice were housed separately with free access to running wheels from 5 months to 24 months of age. Only full wheel rotations were monitored and recorded every night automatically for 12 hours. A threshold of 1500 revolutions per night was defined for data analysis in order to eliminate obstructed running wheels or passive animals.
Open field as a test for initial locomotion and activity of S1/S2 mice was performed for 10 min in a 50 3 50 cm illuminated arena, border zone was defined as area 8 cm from the wall, center zone area was determined as 16% of total arena (20 x 20 cm). Mice were placed in the center zone and recorded from above. Data were analyzed by Viewer 2 tracking software (Biobserve GmbH, Bonn, Germany). S1/S2 mice anxiety-related behavior was investigated using the elevated plus-maze, raised 60 cm off the floor. The maze had two open and two closed arms with similar lengths (wall height of closed arms: 16 cm), connected by a central platform of 5 3 5 cm. Animals were placed in the center, facing the same open arm. Mice were tested for 5 min and recorded from above using the Viewer 2 tracking software (Biobserve GmbH, Bonn, Germany).
HPLC Analysis of Dopamine, Serotonin, and Metabolites
Animals were sacrificed by cervical dislocation, brains were quickly dissected and striatum as well as substantia nigra were isolated on ice using a mouse coronal brain matrix (CellPoint Scientific, Gaithersburg, MD, USA). Samples were weighed, snap-frozen in liquid nitrogen and stored overnight at À80 C. Tissue was homogenized in 0.4 M perchloric acid using a Sonopuls GM 70 ultrasound homogenizer (Bandelin, Berlin, Germany), centrifuged for 15 min at 20.800 g and 4 C and the supernatant was filtered through 0.2 mm syringe filter. The filtered postmortem tissue samples were analyzed for dopamine (DA) and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC), 3-methoxytyramine (3-MT) and homovanillic acid (HVA), as well as for serotonin (5-HT) and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) by high-performance liquid chromatography coupled with electrochemical detection (HPLC-ECD) under isocratic conditions. The detector potential was set at +650 mV using a glassy carbon electrode and an Ag/AgCl reference electrode (BAS MF-1000, Bioanalytical Systems, West Lafayette, IN, USA) at a range of 1 nA/10 V. Injections of 20 ml per sample were done by an auto-cooling autosampler set at 4 C. For chromatographic separation, a reversed phase column was used (100 3 2.1 mm i.d. with pre-column 10 3 2.1 mm i.d., filled with ODS-AQ, 120 Å , 3 mm, YMC Europe GmbH, Dinslaken, Germany). The mobile phase consisted of 1.7 mM 1-octanesulfonic acid sodium salt, 1.0 mM Na 2 EDTA 3 2 H 2 O, 8.0 mM NaCl, 100.0 mM NaH 2 PO 4 3 2 H 2 O, adjusted to pH 3.80 with H 3 PO 4 , filtered through a 0.22 mm filter, mixed up with acetonitrile (final concentration 9.3% v/v) and was delivered at 0.4 ml/min. For data acquisition and calculation, Chromeleon version 6.5 HPLC software (Dionex, Idstein, Germany) was used. The position and areas of the peaks of the neurotransmitters of interest were compared with external standards using a standard calibration ranging from 10 À9 to 10 À6 M. The neurotransmitter amounts were expressed as ng/mg wet tissue weight. For DA and 5-HT turnover, the ratios of (DOPAC + 3-MT + HVA)/DA and 5-HIAA/5-HT were calculated, respectively.
Tyrosine Hydroxylase Staining
Animals were anaesthetized and transcardially perfused with PBS and 4% PFA. Brains were dissected, postfixed for 24 h in 4% PFA at 4 C followed by incubation for 24-48 h in 30% sucrose at 4 C. Brains were embedded in Tissue-Tek O.C.T (Sakura, Leiden, Netherlands) and 40 mm coronal free-floating cryostat sections were systematically sampled throughout the entire brain. Sections were stored in storage solution (1 L PBS, 1 L ethylene glycol, 20 g polyvinylpyrrolidone (PVP)) at 4 C. For staining, sections were washed in PBS, treated with 3% H 2 O 2 , rinsed with PBS and permeabilized + blocked in 0.3% Triton X-100, 5% goat serum, 1% BSA, 1% PVP for 1 h at RT. Primary antibody anti-Tyrosine hydroxylase (Merck, Darmstadt, Germany) diluted 1:400 in PBS + 1% BSA + 0.3% Triton X-100 was incubated for 48 h at 4 C. After 30 min washing in PBS, sections were incubated 2 h at RT with HRP-conjugated goat secondary antibody (Thermo Fisher Scientific, Waltham, MA, USA), washed again for 30 min in PBS and treated with DAB for color development. Sections were washed, mounted on microscope slides, air-dried and covered with DPX medium (Sigma-Aldrich, St. Louis, MO, USA) and glass coverslips. Images were acquired using a MIRAX Scan (Zeiss, Oberkochen, Germany). Corrected optical density measurement for striatal TH quantification was performed by tracing boundaries of both striata (5 -8 sections per animal) with ImageJ (NIH) and measuring mean gray levels of inverted 8-bit images. Cortical staining intensities were used for background correction. Because staining intensity varies between different batches, we performed a pairwise analysis of animals stained simultaneously.
TH Cell Counting (Method A)
Number of TH-positive cells were estimated with random sampling of about every third section to yield 5 sections per mouse per substantia nigra (SN). The number of tyrosine hydroxylase (TH) positive neurons was counted in the SN pars compacta (SNpc) of S1/S2 ± dox and V1S/SV2 ± dox mice at 5 months (N = 5 animals per group) and 24 months (N = 6 animals per group). Experimenters were blinded to genotype and treatment. SNpc boundaries were delimited and cell count analysis was automatically performed using open source QuPath software (Queen's University Belfast, UK) (Bankhead et al., 2017) . Results were manually verified and corrected if necessary (deleted false-positive, included false-negative). For TH-positive cell count analysis, different layers of SN were categorized into six classes with equal weight (1-6; see Figure S8 ). Each brain section was assigned to its designated category (1-6) and the cell count was normalized to the mean value of control animals (transgene off) within the same category. For final data analysis, the values per animal over all categories were averaged in order to have one final value per animal, representing the percentage loss/gain compared to control animals.
TH Cell Counting (Method B)
Dopaminergic neurons were quantified by stereologically counting TH-positive cells in the SNpc of the right hemisphere using the optical fractionator method (StereoInvestigator v7.5 ;MBF Bioscience, Williston, VT, USA), a CX9000 camera (MBF Bioscience) and an Axioskop 2 microscope with 40x/0,75 objective (Zeiss, Jena, German). In every fifth 40 mm section spanning bregma levels À2.8 mm to À3.8 mm, neurons were manually identified in 100x100 mm counting frames. The grid size was 100x100 mm, i.e., the entire area of the SN was analyzed. For the V1S/SV2 animals, we stained two sets of sections from each animal (i.e., sections 1, 6, . and 2, 7, .) and averaged the results. Counting was performed blinded for genotype and treatment. For blinding the slides were pseudonymed using intransparent tape by a technician not involved in the analysis.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed with SAS (Version 9.4, https://www.sas.com) and Prism (GraphPad Prism Version 6.01, https:// www.graphpad.com). Normal distribution of data was tested with D'Agostino & Pearson omnibus normality test, Shapiro-Wilk normality test and KS normality test. Mann-Whitney U test (unpaired data) was used for data from non-Gaussian distribution. Paired t test was used for paired data from Gaussian distribution. 1way ANOVA with Tukey's post hoc test and 2way ANOVA with Tukey's or Sidak's post hoc test were used for multiple comparisons. For behavioral analysis, repeated-measures 2way ANOVA was performed. All tests for significance were two tailed with a = 0.05. Statistical details and the meaning of ''n'' can be found in the figure legends.
DATA AND CODE AVAILABILITY
RNA sequencing dataset of 24 months old V1S/SV2 mice has been uploaded to GEO. The accession number for the sequencing data reported in this paper is GEO: GSE134462.
